• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

机器学习预测非酒精性脂肪肝向非酒精性脂肪性肝炎或肝纤维化的进展

Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

作者信息

Ghandian Sina, Thapa Rahul, Garikipati Anurag, Barnes Gina, Green-Saxena Abigail, Calvert Jacob, Mao Qingqing, Das Ritankar

机构信息

Department of Data Science Houston Texas USA.

Department of Research and Writing Houston Texas USA.

出版信息

JGH Open. 2022 Mar 8;6(3):196-204. doi: 10.1002/jgh3.12716. eCollection 2022 Mar.

DOI:10.1002/jgh3.12716
PMID:35355667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8938756/
Abstract

BACKGROUND

Non-alcoholic fatty liver (NAFL) can progress to the severe subtype non-alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs. Current machine learning studies detect NASH; however, this study is unique in predicting the progression of NAFL patients to NASH or fibrosis.

AIM

To utilize clinical information from NAFL-diagnosed patients to predict the likelihood of progression to NASH or fibrosis.

METHODS

Data were collected from electronic health records of patients receiving a first-time NAFL diagnosis. A gradient boosted machine learning algorithm (XGBoost) as well as logistic regression (LR) and multi-layer perceptron (MLP) models were developed. A five-fold cross-validation grid search was utilized for hyperparameter optimization of variables, including maximum tree depth, learning rate, and number of estimators. Predictions of patients likely to progress to NASH or fibrosis within 4 years of initial NAFL diagnosis were made using demographic features, vital signs, and laboratory measurements.

RESULTS

The XGBoost algorithm achieved area under the receiver operating characteristic (AUROC) values of 0.79 for prediction of progression to NASH and 0.87 for fibrosis on both hold-out and external validation test sets. The XGBoost algorithm outperformed the LR and MLP models for both NASH and fibrosis prediction on all metrics.

CONCLUSION

It is possible to accurately identify newly diagnosed NAFL patients at high risk of progression to NASH or fibrosis. Early identification of these patients may allow for increased clinical monitoring, more aggressive preventative measures to slow the progression of NAFL and fibrosis, and efficient clinical trial enrollment.

摘要

背景

非酒精性脂肪肝(NAFL)可进展为严重亚型非酒精性脂肪性肝炎(NASH)和/或肝纤维化,这与发病率、死亡率和医疗费用增加相关。目前的机器学习研究可检测NASH;然而,本研究在预测NAFL患者进展为NASH或肝纤维化方面具有独特性。

目的

利用NAFL诊断患者的临床信息预测进展为NASH或肝纤维化的可能性。

方法

从首次诊断为NAFL的患者的电子健康记录中收集数据。开发了梯度提升机器学习算法(XGBoost)以及逻辑回归(LR)和多层感知器(MLP)模型。采用五折交叉验证网格搜索对变量进行超参数优化,包括最大树深度、学习率和估计器数量。使用人口统计学特征、生命体征和实验室测量结果预测在初次诊断为NAFL后4年内可能进展为NASH或肝纤维化的患者。

结果

在保留集和外部验证测试集上,XGBoost算法预测进展为NASH的受试者工作特征曲线下面积(AUROC)值为0.79,预测肝纤维化的AUROC值为0.87。在所有指标上,XGBoost算法在NASH和肝纤维化预测方面均优于LR和MLP模型。

结论

有可能准确识别新诊断的有进展为NASH或肝纤维化高风险的NAFL患者。早期识别这些患者可能有助于加强临床监测、采取更积极的预防措施以减缓NAFL和肝纤维化的进展,以及高效地进行临床试验入组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/8de1ec842f66/JGH3-6-196-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/83062d09affc/JGH3-6-196-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/9d15a9edb806/JGH3-6-196-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/8e85b5bf81e7/JGH3-6-196-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/aafdd32069ad/JGH3-6-196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/f093148fb243/JGH3-6-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/8de1ec842f66/JGH3-6-196-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/83062d09affc/JGH3-6-196-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/9d15a9edb806/JGH3-6-196-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/8e85b5bf81e7/JGH3-6-196-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/aafdd32069ad/JGH3-6-196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/f093148fb243/JGH3-6-196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5643/8938756/8de1ec842f66/JGH3-6-196-g003.jpg

相似文献

1
Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.机器学习预测非酒精性脂肪肝向非酒精性脂肪性肝炎或肝纤维化的进展
JGH Open. 2022 Mar 8;6(3):196-204. doi: 10.1002/jgh3.12716. eCollection 2022 Mar.
2
Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.基于组学和有监督学习的非酒精性脂肪性肝炎和肝纤维化的无创诊断:概念验证研究。
Metabolism. 2019 Dec;101:154005. doi: 10.1016/j.metabol.2019.154005. Epub 2019 Nov 9.
3
Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.非酒精性脂肪性肝炎和肝纤维化的精准液体活检。
Gut. 2023 Feb;72(2):392-403. doi: 10.1136/gutjnl-2022-327498. Epub 2022 Jul 12.
4
Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).利用纵向处方和医疗索赔数据进行机器学习,以检测非酒精性脂肪性肝炎(NASH)。
BMJ Health Care Inform. 2022 Mar;29(1). doi: 10.1136/bmjhci-2021-100510.
5
Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients.机器学习方法在非酒精性脂肪肝(NAFL)患者中预测非酒精性脂肪性肝炎(NASH)的应用。
AMIA Annu Symp Proc. 2018 Dec 5;2018:430-439. eCollection 2018.
6
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.非酒精性脂肪性肝病全谱的代谢特征
JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477. eCollection 2022 May.
7
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.使用配对活检评估非酒精性脂肪性肝病从脂肪变性进展为纤维性脂肪性肝炎的证据:对预后和临床管理的影响。
J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.
8
Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers.与肝脏组织学及其他纤维化标志物相比,利用血清IV型胶原快速免疫测定法对非酒精性脂肪性肝病患者进行分类
Hepatol Res. 2017 Feb;47(2):216-225. doi: 10.1111/hepr.12710. Epub 2016 Apr 27.
9
The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis.磁共振弹性成像联合质子密度脂肪分数对非酒精性脂肪性肝炎的诊断价值。
J Magn Reson Imaging. 2022 Aug;56(2):368-379. doi: 10.1002/jmri.28040. Epub 2021 Dec 25.
10
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.一项对随访活检的系统评价显示,非酒精性脂肪肝患者的疾病在进展。
J Hepatol. 2013 Sep;59(3):550-6. doi: 10.1016/j.jhep.2013.04.027. Epub 2013 May 9.

引用本文的文献

1
Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem Cells.利用患者来源的诱导多能干细胞预测代谢功能障碍相关脂肪性肝病风险
bioRxiv. 2025 Jan 15:2025.01.13.632567. doi: 10.1101/2025.01.13.632567.
2
The Potential of Disease Progression Modeling to Advance Clinical Development and Decision Making.疾病进展建模在推进临床开发和决策制定方面的潜力。
Clin Pharmacol Ther. 2025 Feb;117(2):343-352. doi: 10.1002/cpt.3467. Epub 2024 Oct 15.
3
Deep learning for predicting fibrotic progression risk in diabetic individuals with metabolic dysfunction-associated steatotic liver disease initially free of hepatic fibrosis.

本文引用的文献

1
Efficacy and safety of anti-hepatic fibrosis drugs.抗肝纤维化药物的疗效与安全性。
World J Gastroenterol. 2020 Nov 7;26(41):6304-6321. doi: 10.3748/wjg.v26.i41.6304.
2
Identifying High-Risk NASH Patients: What We Know so Far.识别高危非酒精性脂肪性肝炎患者:我们目前所了解的情况。
Hepat Med. 2020 Aug 21;12:125-138. doi: 10.2147/HMER.S265473. eCollection 2020.
3
FDA rejects NASH drug.美国食品药品监督管理局拒绝了非酒精性脂肪性肝炎药物。
深度学习用于预测初始无肝纤维化的代谢功能障碍相关脂肪性肝病糖尿病个体的纤维化进展风险。
Heliyon. 2024 Jul 5;10(13):e34150. doi: 10.1016/j.heliyon.2024.e34150. eCollection 2024 Jul 15.
4
Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques.运用机器学习技术探讨代谢综合征和脂肪性肝病对肝细胞癌的预后影响
Metabolites. 2024 May 27;14(6):305. doi: 10.3390/metabo14060305.
5
An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis.用于预测高危非酒精性脂肪性肝炎的可解释机器学习模型。
Sci Rep. 2024 Apr 13;14(1):8589. doi: 10.1038/s41598-024-59183-4.
6
Machine learning approaches for early detection of non-alcoholic steatohepatitis based on clinical and blood parameters.基于临床和血液参数的非酒精性脂肪性肝炎早期检测的机器学习方法。
Sci Rep. 2024 Jan 30;14(1):2442. doi: 10.1038/s41598-024-51741-0.
7
Machine Learning Differentiation of Autism Spectrum Sub-Classifications.机器学习在自闭症谱系分类中的应用
J Autism Dev Disord. 2024 Nov;54(11):4216-4231. doi: 10.1007/s10803-023-06121-4. Epub 2023 Sep 26.
8
Machine learning determination of applied behavioral analysis treatment plan type.应用行为分析治疗计划类型的机器学习判定
Brain Inform. 2023 Mar 2;10(1):7. doi: 10.1186/s40708-023-00186-8.
9
Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population.用于预测台湾人群脂肪肝疾病的机器学习算法。
J Pers Med. 2022 Jun 23;12(7):1026. doi: 10.3390/jpm12071026.
Nat Rev Drug Discov. 2020 Aug;19(8):501. doi: 10.1038/d41573-020-00126-9.
4
Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare.生物医学与医疗保健领域人工智能中的性别差异与偏见
NPJ Digit Med. 2020 Jun 1;3:81. doi: 10.1038/s41746-020-0288-5. eCollection 2020.
5
Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.单纯性脂肪变性或非酒精性脂肪肝的自然史
J Clin Exp Hepatol. 2020 May-Jun;10(3):255-262. doi: 10.1016/j.jceh.2019.09.005. Epub 2019 Sep 20.
6
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.STELLAR 3和STELLAR 4:从伊卡洛斯陨落中吸取的教训。
J Hepatol. 2020 Jul;73(1):9-11. doi: 10.1016/j.jhep.2020.04.034. Epub 2020 Apr 30.
7
Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.女性患非酒精性脂肪性肝病的风险较低,但进展为该病的风险高于男性:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2021 Jan;19(1):61-71.e15. doi: 10.1016/j.cgh.2020.04.067. Epub 2020 Apr 30.
8
Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.成人非酒精性脂肪性肝病的性别差异。关注临床方面及其对实践和转化研究的影响。
J Clin Med. 2020 Apr 28;9(5):1278. doi: 10.3390/jcm9051278.
9
High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.高通量、基于机器学习的非酒精性脂肪性肝病患者肝活检组织中脂肪变性、炎症、气球样变、纤维化的定量分析。
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2081-2090.e9. doi: 10.1016/j.cgh.2019.12.025. Epub 2019 Dec 27.
10
Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance.非酒精性脂肪性肝病与血小板减少症 III:与胰岛素抵抗的关系。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619888694. doi: 10.1177/1076029619888694.